Phase 2 Alzheimer's Disease Trial, Recruiting
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- People who have been diagnosed with Down syndrome caused by trisomy 21 (having three copies of chromosome 21).
- People whose brain scan (called an amyloid PET scan) shows a build-up of a protein called amyloid.
- People who the trial doctor considers to be cognitively stable (meaning their thinking and memory have not been noticeably declining).
- People who have seizures that are well managed, with no seizures occurring in the six months before the screening visit.
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- People who have severe intellectual disability.
- People who have a history of Down syndrome regression disorder (a condition where a person with Down syndrome experiences a sudden decline in skills and abilities).
- People whose liver enzyme levels (called ALT or AST) are more than twice the upper limit of the normal range at their screening visit.
- People whose kidney filtering function (measured by a test called eGFR) is below a certain level at their screening visit.
- People who have recently taken part in another clinical trial or received an experimental treatment.
- People who have previously been treated with a type of medicine that targets amyloid in the brain.
- People who have other health conditions, such as obstructive sleep apnea (interrupted breathing during sleep) or an underactive thyroid, that are not well managed.
- Additional criteria not listed here may also apply (confirm with trial site).
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Medical Director, Alnylam Pharmaceuticals
Phone: 1-877-ALNYLAM
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Double-Blind Period: Change from baseline in brain amyloid burden measured in centiloids (CLs)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 13 August 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.